TELES Aktiengesellschaft: Change in the Executive Board of TELES AG

Berlin (pta027/07.11.2023/18:00 UTC+1)

Oliver Olbrich, CEO of TELES AG, will leave the company at his own request at the end of 2023. After almost 13 years as a board member - and since 2015 as CEO - he will dedicate himself to new entrepreneurial tasks.

The supervisory board deeply regrets Mr. Olbrich's decision. The Supervisory Board thanks Mr. Olbrich for his years of successful work. Mr. Olbrich transformed TELES AG from a telecommunications company to a pharmaceutical company.

The Supervisory Board appointed Sascha Knoche as his successor on January 1, 2024. Sascha Knoche is currently managing director of the group subsidiary EURO RX Arzneimittel GmbH, Wedemark.

About TELES AG (ISIN DE000A289B07 / WKN A289B0):

TELES is a specialized pharmaceutical supplier that ensures optimal pharmaceutical care for patients with a digitalized supply chain. Medicines for cancer, autoimmune deficiencies and combination therapies for personalized medicine are delivered quickly and reliably throughout Europe.

The need for indication-specific drugs is increasing across Europe and TELES is benefiting from this growth. The European pharmaceutical market is a stable growth market and TELES supplies predominantly German medicines with a high export share. TELES is one of the largest specialty pharmacy companies in Germany.

(end)

Emitter:	TELES Aktiengesellschaft Ordensmeisterstraße 15-16 12099 Berlin Germany
Contact Person:	Oliver Olbrich
Phone:	+49 30 39928 230
E-Mail:	ir@teles.com
Website:	www.teles.com
ISIN(s):	DE000A289B07 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt, Tradegate (Regulated Market); Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart